SAB Biotherapeutics, Inc. (SABSW) Financials

SABSW Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 248.5 million 21.2 million
Dec. 31, 2025 172.8 million 21.3 million
Sept. 30, 2025 183.4 million 18.4 million
June 30, 2025 30.1 million 18.1 million

SABSW Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -15.3 million 5.5 million
Dec. 31, 2025 -17.7 million 3.2 million
Sept. 30, 2025 -13.1 million 187813
June 30, 2025 -7.2 million 627198

SABSW Net Income

No data available :(

SABSW Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 107.4 million 5.3 million 6.2 million
Dec. 31, 2025 96.6 million - 6.0 million
Sept. 30, 2025 110.9 million - 6.2 million
June 30, 2025 5.7 million - 6.4 million

SABSW Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 53.6 million
Dec. 31, 2025 61.3 million
Sept. 30, 2025 77.9 million
June 30, 2025 9.3 million

SABSW Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 983260 13.4 million 5.9 million -730965
Dec. 31, 2025 933155 10.7 million 5.0 million -
Sept. 30, 2025 3 8.9 million 3.7 million -
June 30, 2025 4 7.0 million 2.7 million -

SABSW Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 752670
Dec. 31, 2025 - 763299
Sept. 30, 2025 - 765469
June 30, 2025 - 822000

SABSW

Price: $0.01

52 week price:
0.01
0.05

Earnings Per Share: 0.29 USD

P/E Ratio: 0.06

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 501

Market Capitalization: 160577

Links: